Top 5 Drug Type | Count |
---|---|
Small molecule drug | 44 |
Monoclonal antibody | 10 |
Antibody drug conjugate (ADC) | 9 |
Recombinant LBP | 6 |
Enzyme | 4 |
Target |
Mechanism IL-36R inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date01 Sep 2022 |
Target |
Mechanism PD-1 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. CN |
First Approval Date26 Dec 2019 |
Target |
Mechanism dabigatran inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date16 Oct 2015 |
Start Date20 Mar 2024 |
Sponsor / Collaborator |
Start Date27 Feb 2024 |
Sponsor / Collaborator |
Start Date06 Feb 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Empagliflozin ( SGLT2 ) | Chronic heart failure More | Approved |
Afatinib Dimaleate ( EGFR x EGFR L858R x EGFR-Ex19del x HER2 x HER4 ) | metastatic non-small cell lung cancer More | Approved |
Amlodipine Besylate/Telmisartan ( AT1R x VDCCs ) | Essential Hypertension More | Approved |
Idarucizumab ( dabigatran ) | Hemorrhage More | Approved |
Tenecteplase ( PLG ) | Acute myocardial infarction More | Approved |